{"id":55920,"date":"2023-04-18T01:03:59","date_gmt":"2023-04-17T23:03:59","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\/"},"modified":"2023-04-18T01:03:59","modified_gmt":"2023-04-17T23:03:59","slug":"boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\/","title":{"rendered":"Boomerang Medical Announces First Patients Enrolled in Multi-Center Clinical Trial Evaluating Breakthrough Bioelectronic Device for Inflammatory Bowel Disease"},"content":{"rendered":"
\n

\nKansas Gastroenterology, LLC and Columbia University Irving Medical Center Enroll First Patients in Nation in Clinical Trial of Boomerang Medical’s Nerve Stimulation Device for Crohn’s Disease and Ulcerative Colitis<\/p>\n

<\/a><\/p>\n

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Boomerang Medical, a women-led bioelectronic medicine company, has announced the enrollment of the first patients in its U.S. clinical trial evaluating the use of nerve stimulation as a potential treatment for Crohn\u2019s disease and ulcerative colitis, the two most common forms of Inflammatory Bowel Disease (IBD). This study marks a significant milestone for the company, which was granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) earlier this year for its bioelectronic technology targeting the treatment of IBD.<\/p>\n

\nThe trial will primarily examine the safety and performance of the device in patients with mild to moderately severe Crohn\u2019s disease and ulcerative colitis, regardless of whether they have previously undergone advanced therapy such as biologics. Kansas Gastroenterology, LLC in Wichita, Kansas, enrolled the first patient in the study, followed by Columbia University Irving Medical Center in New York, NY.<\/p>\n

\n\u201cCrohn\u2019s disease and ulcerative colitis remain very difficult to manage, despite the numerous approved biologic therapies available,\u201d said Michael Lievens, M.D., principal investigator for the Boomerang trial at Kansas Gastroenterology, LLC. \u201cThe Boomerang clinical trial aims to investigate a novel alternative intervention \u2013 a device to treat IBD. We are excited to be investigating this promising new treatment.\u201d<\/p>\n

\n\u201cThe most fascinating aspect of this study is the possibility of managing IBD simply by stimulating the patient\u2019s autonomic system to release anti-inflammatory mediators,\u201d said Marco Zoccali, M.D., FACS, principal investigator for the Boomerang trial at Columbia University Irving Medical Center.<\/p>\n

\n\u201cWe are thrilled to enroll the first patients in this clinical trial of our breakthrough bioelectronic device for IBD,\u201d said Heather Simonsen, CEO of Boomerang Medical. \u201cThis trial represents a major milestone in our efforts to develop a new therapeutic approach for patients suffering from Crohn’s disease and ulcerative colitis. We are grateful for the support of our clinical trial partners and the FDA, and we look forward to advancing this important work.\u201d<\/p>\n

\nInflammatory Bowel Disease (IBD) is a chronic, idiopathic inflammatory condition affecting the gastrointestinal tract. The two most common forms of IBD are Crohn’s disease and ulcerative colitis. Despite the availability of several approved biologic therapies, managing IBD remains a significant challenge. Non-response or loss of response to therapy is common, leaving patients to suffer from disease symptoms. In addition, surgical intervention is often required for medically refractory disease. As a result, there is a clear need for additional therapeutic options for IBD.<\/p>\n

\nFor more information about the clinical trial and Boomerang Medical\u2019s bioelectronic technology, please visit www.boomerangmedical.com<\/a>.<\/p>\n

\nAbout Columbia University Irving Medical Center<\/p>\n

\nColumbia University Irving Medical Center (CUIMC) is a leader in providing comprehensive patient care and offers a range of general and specialized medical, dental, and nursing services. We have more than 1,800 physicians, surgeons, dentists, and nurses in locations throughout the New York City metro area. Our knowledge of innovative treatments is enhanced by our compassion for patients and their families and a devotion to maintaining the highest standard of care.<\/p>\n

\nFor more information about Columbia University Irving Medical Center, visit https:\/\/www.cuimc.columbia.edu\/<\/a>.<\/p>\n

\nFor information about our Colorectal and IBD Care Programs, please visit https:\/\/columbiasurgery.org\/colorectal<\/a>.<\/p>\n

\nAbout Kansas Gastroenterology, LLC<\/p>\n

\nKansas Gastroenterology, LLC is a physician-owned practice where our priority is to deliver high quality efficient, compassionate, and patient-centered care. Our five physicians, six physician assistants, and staff are dedicated to providing the individual attention all patients deserve. We look forward to seeing patients for an office consultation, for a procedure in our Ambulatory Surgery Center, or in our new Infusion Center. Our Research department is continually reviewing opportunities to include patients in exciting and beneficial clinical trials.<\/p>\n

\nAbout Boomerang Medical, Inc.<\/p>\n

\nBoomerang Medical is a women-led bioelectronic medicine company on a mission to disrupt how we treat autoimmune diseases. Our innovative technology, granted Breakthrough Device Designation by the Food and Drug Administration (FDA), applies mild electrical impulses to peripheral nerves intended to decrease the inflammation caused by autoimmune disease. Headquartered in the heart of Silicon Valley on the campus of El Camino Hospital, Boomerang is a Company-In-Residence at the prestigious Fogarty Innovation incubator \u2013 the only healthcare-focused incubator\/accelerator of its kind in the U.S. \u2013 giving us access to the brightest minds and expertise in the medical technology industry.<\/p>\n

Contacts<\/b> <\/p>\n

\nPharoah Garma
\n
info@boomerangmedical.com<\/a>
(844) 423-9747<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Kansas Gastroenterology, LLC and Columbia University Irving Medical Center Enroll First Patients in Nation in Clinical Trial of Boomerang Medical’s Nerve Stimulation Device for Crohn’s Disease and Ulcerative Colitis MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Boomerang Medical, a women-led bioelectronic medicine company, has announced the enrollment of the first patients in its U.S. clinical trial evaluating the use … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55920","6":"format-standard","7":"category-industry"},"yoast_head":"\nBoomerang Medical Announces First Patients Enrolled in Multi-Center Clinical Trial Evaluating Breakthrough Bioelectronic Device for Inflammatory Bowel Disease - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boomerang Medical Announces First Patients Enrolled in Multi-Center Clinical Trial Evaluating Breakthrough Bioelectronic Device for Inflammatory Bowel Disease - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Kansas Gastroenterology, LLC and Columbia University Irving Medical Center Enroll First Patients in Nation in Clinical Trial of Boomerang Medical’s Nerve Stimulation Device for Crohn’s Disease and Ulcerative Colitis MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Boomerang Medical, a women-led bioelectronic medicine company, has announced the enrollment of the first patients in its U.S. clinical trial evaluating the use ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-17T23:03:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230417005883\/en\/1727731\/21\/Boomerang_Logo_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Boomerang Medical Announces First Patients Enrolled in Multi-Center Clinical Trial Evaluating Breakthrough Bioelectronic Device for Inflammatory Bowel Disease\",\"datePublished\":\"2023-04-17T23:03:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\\\/\"},\"wordCount\":774,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230417005883\\\/en\\\/1727731\\\/21\\\/Boomerang_Logo_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\\\/\",\"name\":\"Boomerang Medical Announces First Patients Enrolled in Multi-Center Clinical Trial Evaluating Breakthrough Bioelectronic Device for Inflammatory Bowel Disease - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230417005883\\\/en\\\/1727731\\\/21\\\/Boomerang_Logo_RGB.jpg\",\"datePublished\":\"2023-04-17T23:03:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230417005883\\\/en\\\/1727731\\\/21\\\/Boomerang_Logo_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230417005883\\\/en\\\/1727731\\\/21\\\/Boomerang_Logo_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boomerang Medical Announces First Patients Enrolled in Multi-Center Clinical Trial Evaluating Breakthrough Bioelectronic Device for Inflammatory Bowel Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Boomerang Medical Announces First Patients Enrolled in Multi-Center Clinical Trial Evaluating Breakthrough Bioelectronic Device for Inflammatory Bowel Disease - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\/","og_locale":"en_US","og_type":"article","og_title":"Boomerang Medical Announces First Patients Enrolled in Multi-Center Clinical Trial Evaluating Breakthrough Bioelectronic Device for Inflammatory Bowel Disease - Pharma Trend","og_description":"Kansas Gastroenterology, LLC and Columbia University Irving Medical Center Enroll First Patients in Nation in Clinical Trial of Boomerang Medical’s Nerve Stimulation Device for Crohn’s Disease and Ulcerative Colitis MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Boomerang Medical, a women-led bioelectronic medicine company, has announced the enrollment of the first patients in its U.S. clinical trial evaluating the use ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-17T23:03:59+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230417005883\/en\/1727731\/21\/Boomerang_Logo_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Boomerang Medical Announces First Patients Enrolled in Multi-Center Clinical Trial Evaluating Breakthrough Bioelectronic Device for Inflammatory Bowel Disease","datePublished":"2023-04-17T23:03:59+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\/"},"wordCount":774,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230417005883\/en\/1727731\/21\/Boomerang_Logo_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\/","url":"https:\/\/pharma-trend.com\/en\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\/","name":"Boomerang Medical Announces First Patients Enrolled in Multi-Center Clinical Trial Evaluating Breakthrough Bioelectronic Device for Inflammatory Bowel Disease - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230417005883\/en\/1727731\/21\/Boomerang_Logo_RGB.jpg","datePublished":"2023-04-17T23:03:59+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230417005883\/en\/1727731\/21\/Boomerang_Logo_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230417005883\/en\/1727731\/21\/Boomerang_Logo_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/boomerang-medical-announces-first-patients-enrolled-in-multi-center-clinical-trial-evaluating-breakthrough-bioelectronic-device-for-inflammatory-bowel-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Boomerang Medical Announces First Patients Enrolled in Multi-Center Clinical Trial Evaluating Breakthrough Bioelectronic Device for Inflammatory Bowel Disease"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55920"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55920\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}